EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department

Joseph O'Brien iD, Mayher Patel, Joseph Brown iD, Ryan Tucker iD, John Rague

Academic Emergency Medicine · 2026-11 · 33 (11)

DOI: 10.1111/acem.70436 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Academic Emergency Medicine, online erschienen am 04.11.2026. Verfasst von Joseph O'Brien und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Denver Health Medical Center, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Droperidol, Haloperidol, Ondansetron, Antiemetics. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cannabinoid hyperemesis syndrome (CHS) is an increasingly frequent emergency department (ED) presentation. Although ondansetron is commonly used, emerging evidence suggests haloperidol and droperidol may provide more effective symptom control. Robust comparative effectiveness data, particularly regarding short‐term ED recidivism, remain limited.

Methods

We conducted a multicenter retrospective cohort study using the TriNetX Research Network from 2014 to 2024. Adults presenting to the ED with vomiting‐related and cannabis‐related ICD‐10 diagnoses who received haloperidol, droperidol, or ondansetron during the index encounter were included. Patients with alternative causes of vomiting or major confounding conditions were excluded. Propensity‐score matching was performed for three pairwise comparisons: haloperidol versus ondansetron, droperidol versus ondansetron, and droperidol versus haloperidol. The primary outcome was 72‐h ED recidivism. Secondary outcomes included 72‐h hospital admission, 7‐day ED recidivism, and coded adverse events. Multivariable Cox proportional hazards modeling evaluated independent predictors of 72‐h ED recidivism.

Results

After matching, haloperidol was associated with lower 72‐h ED recidivism compared with ondansetron (8.2% vs. 15.1%; OR 0.50, 95% CI 0.41–0.62; p < 0.0001). Droperidol was also associated with lower 72‐h ED recidivism compared with ondansetron (7.4% vs. 14.0%; OR 0.49, 95% CI 0.32–0.76; p = 0.0014). Droperidol and haloperidol did not differ significantly in 72‐h ED recidivism (7.5% vs. 9.8%; OR 0.75, 95% CI 0.47–1.20; p = 0.23). In the multivariable model, haloperidol (HR 0.62, 95% CI 0.49–0.79) and droperidol (HR 0.68, 95% CI 0.56–0.83) were independently associated with lower return risk, whereas ondansetron was not. Coded adverse events were rare across all groups.

Conclusions

In this large multicenter cohort, haloperidol and droperidol were associated with lower short‐term ED recidivism than ondansetron among adults meeting a suspected CHS phenotype. These findings support prospective studies evaluating haloperidol and droperidol for ED management of CHS, including optimal dosing, route, medication sequencing, discharge treatment, and safety monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DroperidolHaloperidolOndansetronAntiemeticsCannabinoid Hyperemesis SyndromeHumansRetrospective StudiesMaleEmergency Service, HospitalFemaleAdultMiddle Aged

Substanzen

DroperidolHaloperidolOndansetronAntiemetics

Autor:innen und Institutionen

  • Department of Emergency Medicine, Denver Health Medical Center, Denver, Colorado, USA.
  • Department of Medicine, University of Colorado, Anschutz Medical Campus, Colorado, USA.
  • Department of Emergency Medicine, University of Colorado, Anschutz Medical Campus, Colorado, USA.

ORCID-Profile: Joseph O'Brien, Joseph Brown, Ryan Tucker

Zitieren

APA

O'Brien, J., Patel, M., Brown, J., Tucker, R., & Rague, J. (2026). Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department. Academic Emergency Medicine, 33(11). https://doi.org/10.1111/acem.70436

Vancouver

O'Brien J, Patel M, Brown J, Tucker R, Rague J. Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department. Academic Emergency Medicine. 2026;33(11). doi:10.1111/acem.70436

BibTeX
@article{OBrien2026,
  author = {O'Brien, Joseph and Patel, Mayher and Brown, Joseph and Tucker, Ryan and Rague, John},
  title = {Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department},
  journal = {Academic Emergency Medicine},
  year = {2026},
  volume = {33},
  number = {11},
  doi = {10.1111/acem.70436}
}
Kostenlos starten →